PINNACLE-MI
Stories
-
Novartis registers Phase 3 trial of Pacibekitug in patients after a Myocardial Infarction
The study, PINNACLE-MI, plans to enroll 10,000 participants and aims to demonstrate superiority of Pacibekitug over placebo in reducing 3-point coronary major adverse cardiovascular events in participants after a Myocardial Infarction. It is scheduled to start on November 30, 2026, with primary completion expected on October 22, 2030.